Taha Bin Arif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Taha Bin Arif has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Jawad Ahmed
Department of Internal Medicine, Northwest Health Porter, Valparaiso, Indiana, USA
11 shared publications - Faryal Tahir
Internal Medicine, Dow University of Health Sciences, Karachi, PAK
7 shared publications - Farheen Malik
Internal Medicine, Dow University of Health Sciences, Karachi, PAK
6 shared publications Aiman Ali
Internal Medicine, Dow University of Health Sciences, Karachi, PAK
5 shared publications- Zainab Majid
Internal Medicine, Dow University of Health Sciences, Karachi, PAK
5 shared publications Muhammad Khalid
Cardiology, Kansas City University of Medicine and Biosciences, Joplin, USA
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (6)
Advancing Academic Gastroenterology: Reflections From a Social Media Ambassador for ACG Case Reports Journal
- 1 June 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (6)
Open AccessAdvancing Academic Gastroenterology: Reflections From a Social Media Ambassador for ACG Case Reports Journal
- Open Access
- 30 November 2025
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 58 (6) , 843-853
Comparative efficacy and safety of supine versus prone positioning in endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis
Background/Aims: Endoscopic retrograde cholangiopancreatography (ERCP) is conventionally performed in the prone position (PP). Recent studies have shown that the supine position (SP) is an effective alternative, with comparable success rates. We conducted a meta-analysis to directly compare the safety and efficacy of the two ERCP positions.Methods: In line with Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic review was performed through a comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library. Statistical analyses were performed using RevMan, with results considered significant at p<0.05 and reported as odds ratios (ORs) and mean differences (MDs).Results: Eleven studies (24,285 patients) were included in the final analysis. Procedural success was significantly higher in the PP (OR, 0.52; 95% confidence interval [CI], 0.36–0.75; p<0.0004) than the SP. However, no significant difference was observed in procedure times (MD, 0.22; 95% CI, –7.07 to 7.50; p=0.95), number of cardiopulmonary complications (OR, 1.08; 95% CI, 0.47–2.48; p=0.86), or post-ERCP pancreatitis (OR, 1.12; 95% CI, 0.52–2.42; p=0.31) between the two groups.Conclusions: The PP demonstrates superior ERCP success compared to the SP, without prolonging procedure time or increasing the risk of adverse events. However, given the comparable procedure times, incidence of adverse events, and increased comfort for both patients and anesthesiologists, the SP may be a suitable alternative for a select group of patients in whom the PP is not feasible, such as those with morbid obesity or recent abdominal surgery.
- 30 November 2025
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 58 (6) , 843-853
Open AccessComparative efficacy and safety of supine versus prone positioning in endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis
Background/Aims: Endoscopic retrograde cholangiopancreatography (ERCP) is conventionally performed in the prone position (PP). Recent studies have shown that the supine position (SP) is an effective alternative, with comparable success rates. We conducted a meta-analysis to directly compare the safety and efficacy of the two ERCP positions.Methods: In line with Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic review was performed through a comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library. Statistical analyses were performed using RevMan, with results considered significant at p<0.05 and reported as odds ratios (ORs) and mean differences (MDs).Results: Eleven studies (24,285 patients) were included in the final analysis. Procedural success was significantly higher in the PP (OR, 0.52; 95% confidence interval [CI], 0.36–0.75; p<0.0004) than the SP. However, no significant difference was observed in procedure times (MD, 0.22; 95% CI, –7.07 to 7.50; p=0.95), number of cardiopulmonary complications (OR, 1.08; 95% CI, 0.47–2.48; p=0.86), or post-ERCP pancreatitis (OR, 1.12; 95% CI, 0.52–2.42; p=0.31) between the two groups.Conclusions: The PP demonstrates superior ERCP success compared to the SP, without prolonging procedure time or increasing the risk of adverse events. However, given the comparable procedure times, incidence of adverse events, and increased comfort for both patients and anesthesiologists, the SP may be a suitable alternative for a select group of patients in whom the PP is not feasible, such as those with morbid obesity or recent abdominal surgery.
- 9 July 2025
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 27 (1) , 1-28
Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives
Purpose of Review Dysbiosis can disrupt intestinal barrier integrity and impact the immune and nervous systems, playing a significant role in developing disorders of gut-brain interaction (DGBI). This review aims to provide a comprehensive understanding of dysbiosis and its role in DGBI while examining the latest advancements in fecal microbiota transplantation (FMT). It also highlights key challenges in the field and outlines critical directions for future research to optimize FMT strategies, ultimately improving patient outcomes in this evolving treatment area. Recent Findings In DGBI, dysbiosis triggers immune responses, increases gut permeability, and disrupts nervous system signaling, with contributing factors including diet, antibiotics, stress, and infections. Individuals with DGBI exhibit distinct microbial imbalances, such as an increased Firmicutes-to-Bacteroidetes ratio and reduced beneficial bacteria. FMT has shown mixed results, with factors like patient selection, treatment protocols, and microbiome diversity influencing outcomes. While FMT can improve symptoms in refractory irritable bowel syndrome (IBS), effects may fade over time, requiring repeat treatments. Future FMT approaches should focus on targeted microbial interventions, considering the role of archaea, fungi, and microbial metabolites, while prioritizing optimal donor selection and large-scale trials for long-term efficacy. Summary Despite the promising findings, FMT has not yet been widely endorsed in clinical guidelines due to the variability and heterogeneity of the data available. While much of the research has focused on IBS, studies have also explored the impact of FMT on other conditions such as functional diarrhea, functional constipation, and functional dyspepsia, which all exhibit altered microbial profiles.
- 9 July 2025
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 27 (1) , 1-28
Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives
Purpose of Review Dysbiosis can disrupt intestinal barrier integrity and impact the immune and nervous systems, playing a significant role in developing disorders of gut-brain interaction (DGBI). This review aims to provide a comprehensive understanding of dysbiosis and its role in DGBI while examining the latest advancements in fecal microbiota transplantation (FMT). It also highlights key challenges in the field and outlines critical directions for future research to optimize FMT strategies, ultimately improving patient outcomes in this evolving treatment area. Recent Findings In DGBI, dysbiosis triggers immune responses, increases gut permeability, and disrupts nervous system signaling, with contributing factors including diet, antibiotics, stress, and infections. Individuals with DGBI exhibit distinct microbial imbalances, such as an increased Firmicutes-to-Bacteroidetes ratio and reduced beneficial bacteria. FMT has shown mixed results, with factors like patient selection, treatment protocols, and microbiome diversity influencing outcomes. While FMT can improve symptoms in refractory irritable bowel syndrome (IBS), effects may fade over time, requiring repeat treatments. Future FMT approaches should focus on targeted microbial interventions, considering the role of archaea, fungi, and microbial metabolites, while prioritizing optimal donor selection and large-scale trials for long-term efficacy. Summary Despite the promising findings, FMT has not yet been widely endorsed in clinical guidelines due to the variability and heterogeneity of the data available. While much of the research has focused on IBS, studies have also explored the impact of FMT on other conditions such as functional diarrhea, functional constipation, and functional dyspepsia, which all exhibit altered microbial profiles.
- 9 June 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (8) , 735-742
Temporal Trends in Mortality Related to Crohn’s Disease in the United States
Background: Crohn’s disease is a chronic and debilitating inflammatory bowel disease that affects many people worldwide. This study explores mortality trends associated with Crohn’s disease across various age groups, racial and ethnic backgrounds, urban and suburban settings, and census regions. Goals: By examining age-adjusted mortality rates (AAMRs), we identified the disparities in Crohn’s disease-related mortality within demographic and geographic categories of the United States. Study: We analyzed death certificates from the CDC WONDER database (1999 to 2020), calculating AAMR per million people and annual percent change (APC) with 95% CIs. Trends by race, ethnicity, gender, age, census regions, and 2013 urbanization status were assessed using the Joinpoint Regression Program. Results: Between 2018 and 2020, Crohn’s disease-related AAMRs rose sharply (APC 11.18, P=0.03). Most deaths occurred in medical inpatient settings (AAPC 0.228), but fatalities at home significantly increased (AAPC 5.37). After 2018, mortality rose in both men (APC 13.21) and women (APC 10.24). The Midwest had the highest rates (APC 0.56, P=0.04), while the Northeast saw a decline (1999 to 2017) followed by a sharp rise after 2017 (APC 9.64, P=0.0071). Mortality was higher in Whites but rose significantly in both Whites (APC 10.47) and African Americans (APC 20.62) post-2018, while trends among Hispanics showed no significant change. Conclusions: Marked demographic and geographic disparities, particularly the wide gap in AAMRs between Whites and African Americans, underscore the urgent need for targeted interventions, improved access to care, and more comprehensive research to reduce these inequities and enhance patient outcomes.
- 9 June 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (8) , 735-742
Temporal Trends in Mortality Related to Crohn’s Disease in the United States
Background: Crohn’s disease is a chronic and debilitating inflammatory bowel disease that affects many people worldwide. This study explores mortality trends associated with Crohn’s disease across various age groups, racial and ethnic backgrounds, urban and suburban settings, and census regions. Goals: By examining age-adjusted mortality rates (AAMRs), we identified the disparities in Crohn’s disease-related mortality within demographic and geographic categories of the United States. Study: We analyzed death certificates from the CDC WONDER database (1999 to 2020), calculating AAMR per million people and annual percent change (APC) with 95% CIs. Trends by race, ethnicity, gender, age, census regions, and 2013 urbanization status were assessed using the Joinpoint Regression Program. Results: Between 2018 and 2020, Crohn’s disease-related AAMRs rose sharply (APC 11.18, P=0.03). Most deaths occurred in medical inpatient settings (AAPC 0.228), but fatalities at home significantly increased (AAPC 5.37). After 2018, mortality rose in both men (APC 13.21) and women (APC 10.24). The Midwest had the highest rates (APC 0.56, P=0.04), while the Northeast saw a decline (1999 to 2017) followed by a sharp rise after 2017 (APC 9.64, P=0.0071). Mortality was higher in Whites but rose significantly in both Whites (APC 10.47) and African Americans (APC 20.62) post-2018, while trends among Hispanics showed no significant change. Conclusions: Marked demographic and geographic disparities, particularly the wide gap in AAMRs between Whites and African Americans, underscore the urgent need for targeted interventions, improved access to care, and more comprehensive research to reduce these inequities and enhance patient outcomes.
- Top Cited Papers
- 30 April 2025
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 37 (12) , 1314-1325
Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis
Functional gastrointestinal disorders impact 40% of the global population, with irritable bowel syndrome (IBS) standing out due to its complexity, quality-of-life effects, and economic impact. Our meta-analysis explored the global prevalence of IBS, considering diagnostic criteria, subtypes, sampling methods, geographical variations, and risk factors. The literature search used databases like PubMed and Cochrane Library, focusing on IBS studies from 2006 to June 2024. Eligibility criteria included studies on individuals aged ≥18, based on Rome III/IV criteria, using random or convenience sampling. Data on IBS prevalence, subtypes, and sampling methods were extracted, and statistical analysis was performed using Open MetaAnalyst and the review manager. The study reviewed 96 articles on IBS prevalence using Rome III and IV criteria across 52 countries, revealing a global prevalence of 14.1%. Prevalence varied by subtype: IBS-C (26.1%), IBS-D (26.5%), IBS-M (31.4%), and IBS-U (8.3%). IBS-D was more prevalent under Rome III (26.2%), while IBS-C was more common under Rome IV (34.2%). First-world countries like the UK, China, and Japan had the highest prevalence. Females [odds ratios (OR): 1.49], stress (OR: 2.47), anxiety (OR: 2.93), and depression (OR: 2.24) were significantly more prevalent in IBS patients, while no significant differences were found in smoking, alcohol use, or education levels. This meta-analysis reveals regional and subtype variations in IBS prevalence, with psychological factors significantly impacting its development. The influence of sampling techniques and Rome III/IV criteria on prevalence estimates highlights the need for a multidisciplinary treatment approach, with important implications for IBS management.
- 30 April 2025
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 37 (12) , 1314-1325
Top Cited PapersGlobal prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis
Functional gastrointestinal disorders impact 40% of the global population, with irritable bowel syndrome (IBS) standing out due to its complexity, quality-of-life effects, and economic impact. Our meta-analysis explored the global prevalence of IBS, considering diagnostic criteria, subtypes, sampling methods, geographical variations, and risk factors. The literature search used databases like PubMed and Cochrane Library, focusing on IBS studies from 2006 to June 2024. Eligibility criteria included studies on individuals aged ≥18, based on Rome III/IV criteria, using random or convenience sampling. Data on IBS prevalence, subtypes, and sampling methods were extracted, and statistical analysis was performed using Open MetaAnalyst and the review manager. The study reviewed 96 articles on IBS prevalence using Rome III and IV criteria across 52 countries, revealing a global prevalence of 14.1%. Prevalence varied by subtype: IBS-C (26.1%), IBS-D (26.5%), IBS-M (31.4%), and IBS-U (8.3%). IBS-D was more prevalent under Rome III (26.2%), while IBS-C was more common under Rome IV (34.2%). First-world countries like the UK, China, and Japan had the highest prevalence. Females [odds ratios (OR): 1.49], stress (OR: 2.47), anxiety (OR: 2.93), and depression (OR: 2.24) were significantly more prevalent in IBS patients, while no significant differences were found in smoking, alcohol use, or education levels. This meta-analysis reveals regional and subtype variations in IBS prevalence, with psychological factors significantly impacting its development. The influence of sampling techniques and Rome III/IV criteria on prevalence estimates highlights the need for a multidisciplinary treatment approach, with important implications for IBS management.
- Open Access
- 15 March 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (6) , 2723-2728
Recurrent vaginal squamous cell carcinoma mimicking peri-rectal abscess: The role of endoscopic ultrasound
- 15 March 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (6) , 2723-2728
Open AccessRecurrent vaginal squamous cell carcinoma mimicking peri-rectal abscess: The role of endoscopic ultrasound
- Open Access
- 1 March 2025
- Published by Wiley in Journal of Digestive Diseases
- Vol. 26 (3-4) , 113-128
MMF Is an Effective and Safer Treatment Options for Treatment‐Naïve Patients With Autoimmune Hepatitis Compared to Azathioprine: A Systematic Review and Meta‐Analysis
Objectives: Autoimmune Hepatitis (AIH) is a chronic inflammatory liver disease with significant morbidity and mortality if untreated. Current first‐line treatment involves corticosteroids and azathioprine (AZA), which are effective but are associated with significant adverse effects and treatment intolerance. Mycophenolate mofetil (MMF), an immunosuppressive agent with a potentially better safety profile, has emerged as an alternative. This meta‐analysis evaluated the efficacy and safety of MMF compared to AZA in treatment‐naïve AIH patients.Methods: We conducted a systematic review and meta‐analysis in accordance with the Preferred Reporting Items for Systematic reviews and Meta‐Analyses guidelines. Databases were searched for articles published up to May 2024. Statistical analysis was performed using RevMan, employing a random‐effects model.Results: Five studies involving 621 patients were included. MMF showed significantly higher rates of complete biochemical response compared to AZA (odds ratio [OR] 3.64, 95% confidence interval [CI] 2.07–6.40, p < 0.00001) and lower non‐response rates (OR 0.45, 95% CI 0.24–0.85, p = 0.01). Corticosteroid withdrawal rates were also higher in the MMF group (OR 2.89, 95% CI 1.69–4.94, p = 0.0001). Relapse rate and cumulative prednisolone dose were comparable between the two groups. MMF demonstrated a better safety profile, with significantly lower rates of gastrointestinal symptoms (OR 0.46, 95% CI 0.27–0.79, p = 0.005).Conclusions: MMF shows superior efficacy and tolerability compared to AZA in treatment‐naïve AIH patients and may serve as a preferred first‐line therapy, offering improved patient adherence and clinical outcomes. Further randomized controlled trials are warranted to confirm these findings.
- 1 March 2025
- Published by Wiley in Journal of Digestive Diseases
- Vol. 26 (3-4) , 113-128
Open AccessMMF Is an Effective and Safer Treatment Options for Treatment‐Naïve Patients With Autoimmune Hepatitis Compared to Azathioprine: A Systematic Review and Meta‐Analysis
Objectives: Autoimmune Hepatitis (AIH) is a chronic inflammatory liver disease with significant morbidity and mortality if untreated. Current first‐line treatment involves corticosteroids and azathioprine (AZA), which are effective but are associated with significant adverse effects and treatment intolerance. Mycophenolate mofetil (MMF), an immunosuppressive agent with a potentially better safety profile, has emerged as an alternative. This meta‐analysis evaluated the efficacy and safety of MMF compared to AZA in treatment‐naïve AIH patients.Methods: We conducted a systematic review and meta‐analysis in accordance with the Preferred Reporting Items for Systematic reviews and Meta‐Analyses guidelines. Databases were searched for articles published up to May 2024. Statistical analysis was performed using RevMan, employing a random‐effects model.Results: Five studies involving 621 patients were included. MMF showed significantly higher rates of complete biochemical response compared to AZA (odds ratio [OR] 3.64, 95% confidence interval [CI] 2.07–6.40, p < 0.00001) and lower non‐response rates (OR 0.45, 95% CI 0.24–0.85, p = 0.01). Corticosteroid withdrawal rates were also higher in the MMF group (OR 2.89, 95% CI 1.69–4.94, p = 0.0001). Relapse rate and cumulative prednisolone dose were comparable between the two groups. MMF demonstrated a better safety profile, with significantly lower rates of gastrointestinal symptoms (OR 0.46, 95% CI 0.27–0.79, p = 0.005).Conclusions: MMF shows superior efficacy and tolerability compared to AZA in treatment‐naïve AIH patients and may serve as a preferred first‐line therapy, offering improved patient adherence and clinical outcomes. Further randomized controlled trials are warranted to confirm these findings.
- Open Access
- 1 August 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (8) , e01474
Upper Gastrointestinal Bleeding Due to Metastatic Lung Adenocarcinoma in the Stomach and Duodenum
There are very few reports of bloodborne metastasis of lung adenocarcinoma to the gastrointestinal tract, primarily due to poor prognosis and short survival rate of metastasized carcinoma. We present a case of a 79-year-old man with a medical history of lung adenocarcinoma, who presented with complaints of weakness and melena for 1 week. He had symptomatic anemia, for which he was transfused with blood. Esophagogastroduodenoscopy showed a 10 mm sessile polyp in the gastric body that was removed. One month later, the patient presented with a similar complaint, and another esophagogastroduodenoscopy revealed 2 ulcerated lesions in the second portion of the duodenum. These lesions were treated by hemostatic clip placement and heater probe coagulation. Biopsy of lesions demonstrated thyroid transcription factor 1 and Napsin-positive tumor cells, consistent with lung adenocarcinoma. Owing to the poor prognosis of lung adenocarcinoma metastasizing to the lymph nodes, stomach, and duodenum, the patient was transferred to hospice care.
- 1 August 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (8) , e01474
Open AccessUpper Gastrointestinal Bleeding Due to Metastatic Lung Adenocarcinoma in the Stomach and Duodenum
There are very few reports of bloodborne metastasis of lung adenocarcinoma to the gastrointestinal tract, primarily due to poor prognosis and short survival rate of metastasized carcinoma. We present a case of a 79-year-old man with a medical history of lung adenocarcinoma, who presented with complaints of weakness and melena for 1 week. He had symptomatic anemia, for which he was transfused with blood. Esophagogastroduodenoscopy showed a 10 mm sessile polyp in the gastric body that was removed. One month later, the patient presented with a similar complaint, and another esophagogastroduodenoscopy revealed 2 ulcerated lesions in the second portion of the duodenum. These lesions were treated by hemostatic clip placement and heater probe coagulation. Biopsy of lesions demonstrated thyroid transcription factor 1 and Napsin-positive tumor cells, consistent with lung adenocarcinoma. Owing to the poor prognosis of lung adenocarcinoma metastasizing to the lymph nodes, stomach, and duodenum, the patient was transferred to hospice care.
- 10 May 2023
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 98 (8) , 868-869
ChatGPT: A Helpful Tool for Resident Physicians?
An abstract is unavailable. This article is available as a PDF only.
- 10 May 2023
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 98 (8) , 868-869
ChatGPT: A Helpful Tool for Resident Physicians?
An abstract is unavailable. This article is available as a PDF only.
- Top Cited PapersOpen Access
- 21 February 2023
- Published by Taylor & Francis in Medical Education Online
- Vol. 28 (1) , 2181052
The future of medical education and research: Is ChatGPT a blessing or blight in disguise?
To the editor,With the rapid evolution of scientific literature and technology, experts rely more on new artificial intelligence models for convenience and easy access to needs. The introduction of...
- 21 February 2023
- Published by Taylor & Francis in Medical Education Online
- Vol. 28 (1) , 2181052
Top Cited PapersOpen AccessThe future of medical education and research: Is ChatGPT a blessing or blight in disguise?
To the editor,With the rapid evolution of scientific literature and technology, experts rely more on new artificial intelligence models for convenience and easy access to needs. The introduction of...